DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts

Journal of Dermatological Science

Volumn 51, Issue 3, 2008, Pages 171-180

  Makino, Sachio ^a   Mitsutake, Norisato ^a   Nakashima, Masahiro ^b   Saenko, Vladimir A ^a   Ohtsuru, Akira ^c   Umezawa, Kazuo ^d   Tanaka, Katsumi ^a   Hirano, Akiyoshi ^a   Yamashita, Shunichi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^d KEIO UNIVERSITY   (Japan)

Author keywords

DHMEQ; Keloid; NF kappaB; Type I collagen

Indexed keywords

COLLAGEN TYPE 1; DEHYDROXYMETHYLEPOXYQUINOMICIN;

ADULT; ARTICLE; CASE REPORT; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; DNA BINDING; DRUG EFFECT; DRUG MECHANISM; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; PATHOGENESIS; PRIORITY JOURNAL;

BENZAMIDES; CELL DIVISION; CELLS, CULTURED; COLLAGEN TYPE I; CYCLOHEXANONES; DNA; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; KELOID; NF-KAPPA B; TRANSCRIPTION FACTOR RELA;

EID: 48049106913     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2008.03.003     Document Type: Article

References (36)

1. Al-Attar A., Mess S., Thomassen J.M., Kauffman C.L., and Davison S.P. Keloid pathogenesis and treatment. Plast Reconstr Surg 117 (2006) 286-300
2. Atiyeh B.S., Costagliola M., and Hayek S.N. Keloid or hypertrophic scar: the controversy: review of the literature. Ann Plast Surg 54 (2005) 676-680
3. Ghosh S., May M.J., and Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16 (1998) 225-260
4. Luo J.L., Kamata H., and Karin M. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 115 (2005) 2625-2632
5. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 (1999) 6853-6866
6. Yamamoto Y., and Gaynor R.B. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 107 (2001) 135-142
7. Baldwin Jr. A.S. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107 (2001) 3-6
8. Messadi D.V., Doung H.S., Zhang Q., et al. Activation of NFkappaB signal pathways in keloid fibroblasts. Arch Dermatol Res 296 (2004) 125-133
9. Matsumoto N., Ariga A., To-e S., et al. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 10 (2000) 865-869
10. Ariga A., Namekawa J., Matsumoto N., Inoue J., and Umezawa K. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 277 (2002) 24625-24630
11. Umezawa K. Inhibition of tumor growth by NF-kappaB inhibitors. Cancer Sci 97 (2006) 990-995
12. Palona I., Namba H., Mitsutake N., et al. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 147 (2006) 5699-5707
13. Arakawa M., Hatamochi A., Takeda K., and Ueki H. Increased collagen synthesis accompanying elevated m-RNA levels in cultured Werner's syndrome fibroblasts. J Invest Dermatol 94 (1990) 187-190
14. Li N., and Karin M. Signaling pathways leading to nuclear factor-kappa B activation. Methods Enzymol 319 (2000) 273-279
15. Kikuchi E., Horiguchi Y., Nakashima J., et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. Cancer Res 63 (2003) 107-110
16. Nagata K. Hsp47: a collagen-specific molecular chaperone. Trends Biochem Sci 21 (1996) 22-26
17. Naitoh M., Hosokawa N., Kubota H., et al. Upregulation of HSP47 and collagen type III in the dermal fibrotic disease, keloid. Biochem Biophys Res Commun 280 (2001) 1316-1322
18. Watanabe M., Dewan M.Z., Okamura T., et al. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 114 (2005) 32-38
19. Ghazizadeh M., Tosa M., Shimizu H., Hyakusoku H., and Kawanami O. Functional implications of the IL-6 signaling pathway in keloid pathogenesis. J Invest Dermatol 127 (2007) 98-105
20. Kouba D.J., Chung K.Y., Nishiyama T., et al. Nuclear factor-kappa B mediates TNF-alpha inhibitory effect on alpha 2(I) collagen (COL1A2) gene transcription in human dermal fibroblasts. J Immunol 162 (1999) 4226-4234
21. Rippe R.A., Schrum L.W., Stefanovic B., Solis-Herruzo J.A., and Brenner D.A. NF-kappaB inhibits expression of the alpha1(I) collagen gene. DNA Cell Biol 18 (1999) 751-761
22. Bitzer M., von Gersdorff G., Liang D., et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev 14 (2000) 187-197
23. Ishida Y., Kondo T., Kimura A., Matsushima K., and Mukaida N. Absence of IL-1 receptor antagonist impaired wound healing along with aberrant NF-kappaB activation and a reciprocal suppression of TGF-beta signal pathway. J Immunol 176 (2006) 5598-5606
24. Buttner C., Skupin A., and Rieber E.P. Transcriptional activation of the type I collagen genes COL1A1 and COL1A2 in fibroblasts by interleukin-4: analysis of the functional collagen promoter sequences. J Cell Physiol 198 (2004) 248-258
25. Novitskiy G., Potter J.J., Rennie-Tankersley L., and Mezey E. Identification of a novel NF-kappaB-binding site with regulation of the murine alpha2(I) collagen promoter. J Biol Chem 279 (2004) 15639-15644
26. Auphan N., DiDonato J.A., Rosette C., Helmberg A., and Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270 (1995) 286-290
27. Scheinman R.I., Cogswell P.C., Lofquist A.K., and Baldwin Jr. A.S. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270 (1995) 283-286
28. De Bosscher K., Schmitz M.L., Vanden Berghe W., Plaisance S., Fiers W., and Haegeman G. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci USA 94 (1997) 13504-13509
29. Yin M.J., Yamamoto Y., and Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396 (1998) 77-80
30. Zhu G., Cai J., Zhang J., Zhao Y., and Xu B. Abnormal nuclear factor (NF)-kappaB signal pathway and aspirin inhibits tumor necrosis factor alpha-induced NF-kappaB activation in keloid fibroblasts. Dermatol Surg 33 (2007) 697-708
31. Seitz C.S., Freiberg R.A., Hinata K., and Khavari P.A. NF-kappaB determines localization and features of cell death in epidermis. J Clin Invest 105 (2000) 253-260
32. Dajee M., Lazarov M., Zhang J.Y., et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421 (2003) 639-643
33. Seitz C.S., Lin Q., Deng H., and Khavari P.A. Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci USA 95 (1998) 2307-2312
34. van Hogerlinden M., Rozell B.L., Ahrlund-Richter L., and Toftgard R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res 59 (1999) 3299-3303
35. Lim I.J., Phan T.T., Song C., Tan W.T., and Longaker M.T. Investigation of the influence of keloid-derived keratinocytes on fibroblast growth and proliferation in vitro. Plast Reconstr Surg 107 (2001) 797-808
36. Lim I.J., Phan T.T., Bay B.H., et al. Fibroblasts cocultured with keloid keratinocytes: normal fibroblasts secrete collagen in a keloid like manner. Am J Physiol Cell Physiol 283 (2002) C212-C222